

#### Determinazione del Responsabile Ufficio Formazione nº 8 2 6 del 2 8 106. 2015

Oggetto: Aggiornamento senza oneri, Dirigente Medico, Dott. Loi Bruno.

Pubblicata all'Albo Pretorio dell'Azienda Ospedaliera a partire dal 2 8 LUG. 2015 per 15 giorni consecutivi e posta a disposizione per la consultazione.

#### Il Responsabile Ufficio Formazione

Visto

il D. Lgs. n. 502/92 e successive modificazioni ed integrazioni;

Viste

le Leggi Regionali n. 10/2006 e n. 05/2007;

Vista

la Deliberazione n. 263 del 04.03.2015, con la quale il Commissario Straordinario ha autorizzato il Responsabile dell'Ufficio Formazione Dott. Andrea Corrias, a predisporre le

Determinazioni:

Vista

la comunicazione Prot. n° 13998 del 13.07.2015 con la quale la Ditta Edwards Lifesciences Italia S.p.A. si è resa disponibile ad invitare un Medico della S.C. Emodinamica al Congresso:

"PCR London Valves 2015" che si terrà a Berlino dal 20.09.2015 al 22.09.2015;

Considerato

che il Direttore del Dipartimento Patologia Cardiaca ha autorizzato a partecipare al suddetto

Congresso il Dott. Loi Bruno;

Atteso

che il Responsabile dell'Ufficio Formazione ha espresso parere favorevole in merito;

Ritenuto

di dover autorizzare la partecipazione del Dott. Loi Bruno al Congresso: "PCR London Valves 2015" che si terrà a Berlino dal 20.09.2015 al 22.09.2015; di dover prendere atto che le spese di partecipazione saranno totalmente a carico della Ditta Edwards Lifesciences Italia S.p.A.

#### **DETERMINA**

#### Per i motivi esposti in premessa:

- Autorizzare la partecipazione del Dott. Loi Bruno al Congresso: "PCR London Valves 2015" che si terrà a Berlino dal 20.09.2015 al 22.09.2015.
- 2. Dare atto che le spese di partecipazione saranno totalmente a carico della Ditta Edwards Lifesciences S.p.A.
- 3. Trasmettere la presente determinazione al Direttore della S.C. del Personale per gli adempimenti normativi di competenza.

Il Responsabile dell'Ufficio Formazione

Dott. Andrea Corrias
Aululante



Multire Cordiologie

#### Edwards

Spettabile

IL DIRETTORE SANITARIO DEL PRESIDIO DE Marinella Spissu

Ospedale Brotzu

Plazzale Ricchi 1 - 09134 Cagliari c.a. Direzione Amministrativa/Sanitaria

Mittente EDWARDS LIFESCIENCES ITALIA SPA

PG/2015/ 0013998

Assegnatario : Ufficio Formazione

del 13/07/2015 ore 11,53



p.c. Primario di S.C. Cardiochirurgia p.c. Primario di S.C. Emodinamica

Milano, 19 giugno 2015

OGGETTO: PCR London Valves 20 - 22 actembre 2015 (Berlino)

La nostra Società parteciperà ell'iniziativa in oggetto; fermo restando il rispetto della normativa del Ministero della Sanità in medito al fini autorizzativi e procedurali, siamo lieti di invitare: nº 1 cardiochirurgo e nº 1 cardiologo interventista che i Primari di Reparto vorranno segnalare: (del quali la Vs. Amministrazione in plena e totale autoriomia ne deciderà la partecipazione), facendoci carico delle spesa relative all'iscrizione al congresso, al viaggio ed al soggiorno. Il congresso, di natura prettamente scientifica, sara un'ottima occasione per futti i partecipanti per incontrarsi, scambiare idee nonche un aggiornamento su tutti gli aspetti inerenti le materie trattate.

Vi comunichiamo che trascorsi 30 giorni dalla data della presente, nulla ricevendo da parte. Vostra, riterremo accattato il nostro invito.

Vi informiamo Inoltre che al partecipante designato sarà inviata una lettera di conferma di sovvenzione, come da esempio allegato.

Edwards Lifescherices Italia S.p.A.

Angelo C'Aquita - Business Unit Manager

NOME e COGNO	ME:							· ;
FUNZIONE:				., .,	1	<i>i</i> .	 	<u> </u>
DATA:		70	MBRO:			• • •	 •	<u></u>

an JIDA

Edwards Lifesciences Italia \$.p.A.

Seda Legale: Centro Leoni Edincio A.\* Via Giovanti Spadolini, 6 \* 20141 Milano
Tel. 02.56806.1 \* Fax 02.56806.592 \* Www.edwards.com
P.I./C.E. 08008041007 \* Capitale Scoale Euro 124.336,73 int. vars. • Reg. Impress Milano 06068041000 \* R.E.A. 182067

L DIRETTORE DEL DIPARTIMENTO RATOLOGIA CARDIACA Azienda Ospedbilera Brotzi S. C. di Emodinamica Direttore: Dott. Brusp Lo

AZIENDA OSPEDALIERA E. BROTZD UFFICIO, PORZAZATONE



INFORMATIVA ai sensi dell'art. 13 del D. Igs. 196/2003 e successivi aggiornamenti,

Il D. lgs, n. 196 del 30 giugno 2003 ("Codice in materia di protezione dei dati personali") prevede la tutela delle persone e di altri soggetti rispetto al trattamento dei dati personali.

Secondo la normativa Indicata, tale trattamento sarà improntato ai principi di liceità, correttezza, trasparenza e di tutela della Sua riservatezza e dei Suoi diritti.

Ai sensi dell'articolo 13 del D.lgs. n. 198/2003, pertanto, Le forniamo le seguenti informazioni:

- 1. I dati da Lei forniti verranno trattati per le seguenti finalità:
  - finalità di informazione medico-scientifica,
  - invito o segnalazione di congressi, convegni, seminari,
  - Invio di pubblicazioni periodiche od occasionali,
  - informazioni su nuovi prodotti,
  - motodologie, servizi, sia da parte nostra che di nostre società consociate o collegate;
- 1. Il trattamento sarà effettuato con le seguenti modalità, manuale od informatico,
- 2. Il dati possono essere comunicati o diffusi esclusivamente alle società controllanti, controllate, consociate e collegate, alla rete di informatori medico-scientifici, ai nostri fornitori ed eventuali subfornitori, impegnati nella esecuzione di attività connesse ed alle associazioni di categoria.
- 3. Per le finalità sograindicate un Suo rifiuto al conferimento dei dati e del consenso, causerà la nostra impossibilità a procedere: all'iscrizione, con la conseguente mancata partecipazione al congresso stesso ed a farLe pervenire la documentazione sulle altre attività.
- Rispetto ai dati in nostro possesso, Ella potrà sempre esercitare i diritti previsti dall'art.7 che per Sua comodità riproduciamo integralmente.
- 5. La informismo infine che il titolare del trattamento di cui alla presente informativa è la Edwards Lifesciences Italia S.p.A., con sede legale in Via G. Spadolini, 5, 20141 Milano, alla quale Ella potrà rivolgersi per chiarimenti o informazioni aggiuntive.

#### Decreto Legislativo n. 196/2003 e successivi aggiornamenti. Art. 7 - Diritto di accesso ai dati personali ed altri diritti

- 1. L'Interessato ha diritto di ottenere la conferma dell'esistenza o meno di dati personali che lo riguardano, anche se non ancora registrati, e la loro comunicazione in forma intelligibile.
- 2. L'interessato ha diritto di ottenere l'iridicazione:
- a) dell'origine del dati personali;
- b) delle finalità e modalità del trattamento:
- c) della logica applicata in caso di trattamento effettuato con l'ausilio di strumenti elettronici;
- d) degli estremi identificativi del titolare, dei responsabili e del rappresentante designato ai sensi dell'articolo 5, comma 2;



- e) dal soggetti o delle categorie di soggetti al quali i dati personali possono essere comunicati o che possono venime a conoscenza in qualità di rappresentante designato nel territorio dello Stato, di responsabili o incaricati.
- 3. L'interessato ha diritto di ottenere:
- a) l'aggiornamento, la rettificazione ovvero, quando vi ha interesse, l'Integrazione dei dati;
- b) la cancellazione, la trasformazione in forma anonima o il blocco del dati trattati in violazione di legge, compresi quelli di cui non è necessaria la conservazione in relazione egli scopi per i quali i dati sono stati reccolti o successivamente trattati;
- c) l'attestazione che le operazioni di cui alle lettere a) e b) sono state portate a conoscenza, anche per quanto riguarda il loro contenuto, di coloro ai quali i dati sono stati comunicati o diffusi, eccettuato il caso in cui tale adempimento si rivela impossibile o comporta un impiego di mezzi manifestamente sproporzionato rispetto al diritto tutelato.
- 4. L'interessato ha diritto di opporsi, in tutto o in parte:
- a) per motivi legittimi al trattamento dei dati personali che lo riguardeno, ancorche pertinenti allo scopo della raccolta;
- b) al frattamento di dati personali che lo riguardano a fini di invio di materiale pubblicitario o di vendita diretta o per il complimento di ricerche di mercato o di comunicazione commerciale.

Consenso dell'interessato
Luogo
William Willia
Nome
JI/La sottoscritto/a, acquisite le informazioni fornite dal titolare del trattamento ai sensi dell'articolo 13 del D.Lgs. 198/2003, l'interessato:
presta il suo consenso al trattamento dei dati personali per I fini indicati nella suddetta informative?
Presto II consenso Nego II consenso
presta il suo consenso per la comunicazione dei dati personali per le finalità ed al soggetti indicati nell'informativa?
Presto il consenso Nego il consenso
presta il suo consenso per la diffusione dei dati personali per le finalità e nell'ambito indicato nell'informativa?
Presto il consenso Nego il сопъелво
Firme dell'interessato



THEAT

Egr dr
Spett le Ente
Città

Oggetto: Conferma dell'assemazione di una sovvenzione per la partecipazione al programma
formativo organizzato da terzi PCR London Valves 2015 - Borlino 20-22 sottombre 2015

でも、「これに動いとして管理なり、 みんれいしょう とうしんり だいさい とうしょうしょ ディ	. •
a nome di Edwards Lifesciences (di seguito "Edwards"), sono lieto di offrirle un educational grant per la partecipazione congresso PCR London Valves (di seguito: "programma Tormativo") che si terrà in data 20 – 22 settembre 2015 presso CityCube -Conference Center- Berlin, Messedamm 22, D-14055 Berlino.  Il programma formativo, che consideriamo una conferenza bona fide indipendente, formativa, scientifica o promotrice di politiche volta a contribuire alla conoscenza scientifica, al progresso medico e/o a un'efficace assistenza sanitaria, è sponsorizzato da Europa Organisation B.P. 61508:31015 Toulouse-France e si prefigge lo scopo di promuovere la formazione nel campo delle patologie che coinvolgono le valvole cardiache. Per praticità, può scaricare il programma collegandosi al sito www.pcrlondonvalves.com.  La scelta è ricaduta su di Lei poiché ci è stato segnalato dal Suo istituto per le Sue competenze mediche, tecniche scientifiche. In conformità con le nostre politiche e procedure, possiamo finanziare la Sua partecipazione a un massimo due (2) programmi formativi per anno solare.	î .
La sovvenzione prevede il rimborso o il pagamento della tassa di iscrizione al programma, formativo, nonche del ragionevoli spese di viaggio, vitto e alloggio correlate alla partecipazione ad esso. Le verrà rimborsata qualunque altispesa sostenuta e pagata (es. spese di taxi, e pasti extra) in relazione all'evento e approvata nel termine di trenta (3 giorni dal ricevimento delle fatture o ricevitte giustificative. Le suddette spese non verranno rimborsate qualora no siano corredate di ricevitta. Inoltro, Edwards non rimborserà alcuna spesa sostenuta per il coniuge o altispetto delle leggi vigenti in Italia e del Codice di condotta aziendale della European Confederation of Medical Supplier Associations ("Eucomed"). L'educational grant non è in alcun modo (i) attribuito a titolo remunerativo per il pregressi utilizzo dei prodotti o servizi di Edwards o per averne raccomandato l'impiego né (ii) è condizionato al futuro acquisto alla raccomandazione dei prodotti o servizi di Edwards od offerto in cambio di essi.	ra O) ro no
	wen
Desidero cogliere l'occasione per informarta che Edwards sta sviluppando un programma in virtù del quale in av potrebbe rendere di pubblico dominio i finanziamenti offerti agli operatori sanitari per la partecipazione a questo e seventi formativi. In caso di domande non esiti a contattarmi.	ıd a
Desidero cogliere l'occasione per informarta che Edwards sta sviluppando un programma in virtù del quale in av potrebbe rendere di pubblico dominio i finanziamenti offerti agli operatori sanitari per la partecipazione a questo e	a ba

## Programme –

## Sunday 20th September, 2015

			325:	3055	1043	8501		10:28	10.23		રાજા		1002	.0%						Plenary session	IMAGING	ROOM 4	11:05-12:20
> Key learnings & session evaluation	> Discussion & audience interaction	what are the benefits?	New Imaging technologies in the catheter laboratory:	> Discussion & audience interaction	Imaging for Mitral intervention: effective use of TOE & CT	> Discussion & audience interaction	positioning	> Imaging for TAVI: annular alignment & optimal prosthesis	> Discussion & audience interaction	TOE?	> Imaging for TAVI: what are the incremental benefits of	modalities are essential?	> Imaging for TAVI with conscious sedation; which	> Session objectives	use in the catheter laboratory	> To learn more about emerging Imaging technologies for	conscious sedation	To appreciate the limitations of Imaging during TAVI with	Imaging techniques in aortic & mitral valve interventions	> To understand the complementary role of different	Attend this session if you want:	need & when?	11:05-12:20 🖾 Imaging for valve interventions: what do we
12:28		1213		शन्या	11:58		11/48	11/40		: (53	1128		31:11	1110						Plenary session	IMAGING	ROOM 4	13:00-14:15
<ul> <li>Discussion &amp; audience interaction</li> <li>Key learnings &amp; session evaluation</li> </ul>	analyse a CT dataset	Assessment of the TAVI candidate (2): how to acquire &	analyse a 3D echocardiography dataset	> Assessment of the TAVI candidate (1): how to acquire &	) Discussion & audience interaction	valvular heart disease	› How to perform & analyse a stress echocardiogram in	> Discussion & audience interaction	aortic stenosis	All you need to know about Low flow & Low gradient	> Discussion & audience interaction	echocardiography	> How to assess patients with multiple valve lesions using	> Session objectives	in complex valvular heart disease	To understand the utility of advanced Imaging techniques	stenosis	> To learn more about Low flow, Low gradient aortic	multiple valve lesions using echocardiography	> To improve your understanding of the assessment of	Attend this session if you want:	lmaging	13:00-14:15 韓 Complex valve disease: the pivotal role of

## Programme -

## ...Sunday 20<sup>th</sup> September, 2015 14:20-15:35 卿 Imaging Basics for TAVI

	15:13 / > Key learnings & session evaluation	15:33 > Discussion & audience interaction	14:58   > Imaging follow-up; what to look for?	15:53 > Discussion & audience interaction	14:43 Detection of common peri-procedural complications	14:38	> Pre-procedural planning: vascular access	14:18 / Pre-procedural planning: valve sizing	14:13 / Discussion & audience interaction	74:03 / Pitfalls in the diagnosis & quantification of AS	14:95 > Session objectives		TAVI a safe & predictable procedure	To know how to use different Imaging modalities to make	scenarios before, during & after TAVI	To improve your recognition of common imaging	Plenary session   candidates	IMAGING   > To understand the challenges of Imaging in TAVI	ROOM 4 Attend this session if you want:	14:20-15:35 🕸 Imaging Basics for TAVI
17:99 17:49 17:55	17:34		17:24	17:19		17:07	17:02		16:50	16:45							Plenary session	IMAGING	ROOM 4	15:46-17:00 B
<ul> <li>Imaging for valve-in-valve procedures: is fluoroscopy sufficient?</li> <li>Discussion &amp; audience interaction</li> <li>Key learnings &amp; session evaluation</li> </ul>	> Discussion & audience interaction	which size?	> Valve-in-valve & valve-in-ring procedures: which valve &	> Discussion & audience interaction	quantitation of paraprosthetic leaks	Assessment of the failing prosthetic valve (2): diagnosis &	> Discussion & audience interaction	patient-prosthesis mismatch	> Assessment of the failing prosthetic valve (1): stenosis &	> Session objectives		performance of interventional treatment options	To appreciate how imaging can guide the selection &	valve-in-valve and valve-in-ring procedures	> To learn how imaging can influence device selection for	failing bio-prosthetic valve	To understand more about the Imaging assessment of a	Attend this session if you want:	Imaging considerations	15:46-17:00 回 The treatment of failing prosthetic valves:

...Sunday 20th September, 2015

#### Not to miss!

EXHIBITION AREA 17:00-18:00 🕸 Welcome reception

Tools & Techniques 18:00-19:40 @ TAVI with the SAPIEN family of valves has MAIN ARENA emerged as a fast, predictable & robust procedure with proven durability With an unrestricted educational grant from Edwards Lifesciences

- Attend this session if you want:

  To understand the status of TAVI in 2015
- To learn about the latest Edwards TAVI valves
- To appreciate the breadth & depth of clinical data
- octogenarians

808 1888 1888

Session objectives
 SAPIEN 3 is the treatment of choice for symptomatic AS in

- 25.03
- > Case demonstration
  > Discussion & audience interaction Procedure efficiency with next day discharge is becoming
- a reality
- durability concern?

1889

Discussion & audience interaction
 Moving into younger patients; have we overcome the

- Case demonstrationDiscussion & audience interaction
- 1935 | > Session evaluation & key learnings

## Monday 21st September, 2015

08:30-08:45 m Welcome to PCR London Valves 2015 MAIN ARENA

LIVE demonstration 08:45-10:00 P LIVE demonstration from Vivantes Klinikum Am MAIN ARENA 35:45 ↑ Time to React@PCR Introduction to LIVE
With continuous LIVE from Vivantes Klinikum Am Urban/im Friedrichshain/DHZB Berlin, Germany Urban/im Friedrichshain/DHZB Berlin, Germany

### 09:30-10:30 🛭 Valve interventions under conscious sedation ROOM 2

Plenary session To appreciate the evidence base for TAVI performed with Attend this session if you want: conscious sedation

To learn how to select the best cases for conscious

To understand how to safely perform TAVI under conscious sedation

Session objectives

69:33 > Recorded LIVE demonstration

99:39 Time to React@PCR

09:46 09:52 > Which patients are best suited to conscious sedation: how Time to React@PCR to do it safely?

› How to ensure optimal peri-procedural Imaging: TTE, nasal TOE or ICE?

Time to React@PCR

16:12 | > Key learnings & session evaluation

09:30-10:30 阿 Learning SAPIEN 3

Attend this session if you want:

To learn about the composition of SAPIEN 3

> To learn how to use SAPIEN 3 in regular & complex

anatomies

ö

...Monday 21st September, 2015

Programme to be advised soon	Call for submissions	09:30-10:30 图 Abstracts
	מטון אמואכט דס ניס מספונמבי	don Values 2015 abstract
	> Programme to be advised soon	

> Programme to be advised soon

09:30-10:30 
Room 6 assessment
Nusses® Attend this session if you want:
technician session To learn how to read a cardiac gated computed tomography scan
> To know how to interpret 3D transoesophageal echocardiographic images

To learn what transthoracic & transpesophageal

echocardiography can add in the catheter lab

Session objectives
 Cardiac gated computed tomography: a beginners guide
 Discussion & audience interaction
 SD transpesophageal echo: a beginners guide
 Discussion & audience interaction
 TAVI Imaging requirements in the era of conscious sedation
 Discussion & audience interaction

09:30-10:30 III Interactive case corner I
Session comprising selected PCR London Valves 2015 clinical case submissions

> Programme to be advised soon

l → Key learnings & session evaluation

PCR London Valves Preliminary programme - Valid as of 5th June, 2015

...Monday 21st September, 2015

#### Not to miss!

10:00-10:30 🌣 Keynote lecture Keynote lecture MAIN ARENA Mitral regurgitation: a disease of the valve & myocardiaum When & how we should intervene

# 11:00-11:30 岡 TAVI in intermediate & lower risk patients

Plenary session Yo learn about the applicability of TAVI in operable lower-Attend this session if you want: To appreciate what is happening in the real world as we To understand the limitations of the available data in this gain more long-term data

- 11:02 1:8 Session objectives
- > The remaining limitations of TAVI: lessons from trials & registries
- 11:07 11:12 Update on the intermediate risk trials
   How should we select TAVI or surgery for intermediate risk patients in 2015?
- Is there a role for minimal access surgery in patients unsuitable for TAVI?

11:17

- 11:22
- Key learnings & session evaluation

#### Time to React@PCR

#### 11:00-11:55 岡 Primary mitral regurgitation: outcomes of Plenary session ROOM 2 treatment surgical repair & implications for percutaneous Attend this session if you want:

- To appreciate current techniques & outcomes of surgical valve repair in primary mitral regurgitation
- To hear the latest clinical data concerning percutaneous treatment alternatives

To discuss the future horizons for optimal treatment

- > Session objectives
- 1168 > Surgical valve repair: the gold standard?
- 11:11 Time to React@PCR
- 11:19 Percutaneous options: latest trials & real world results

17:27

- How do we combine the best of surgical & percutaneous Time to React@PCR techniques? A future vision
- 155 Time to React@PCR
- > Key learnings & session evaluation

#### ROOM 3

### 11:00-12:30 呵 Learning simplifying transfernoral TAVI Attend this session if you want:

- To understand who is a suitable patient for TAVI without general anesthesia
- > To understand how to safely plan & perform a simplified
- To identify the potential benefits of a simplified procedure



PCR London Valves Preliminary programme - Valid as of 5th June, 2015

## Programme -

...Monday 21st September, 2015

											rogramme to be advised soon	ROOM 5	11:00-12:30 📮 Learning MitraClip	Programme to be advised soon		Call for   case submissions	ROOM 4   Session comprising selected PCR London Valves 2015 clinical	11:00-12:30 閟 Forum
11:00-12:30 國 Interactive Case Corner II  call for	 22:19 > Discussion & audience interaction	(Exc. A How did I treat? – Presenter from Germany	11:55 Yow would I treat? – Expert from Germany	11:50 > How would I treat? – Expert from Italy	11:45 > Case presentation from Germany	11:66 Consensus	11:50 Discussion & audience interaction	1120 > How did I treat? – Presenter from Italy	ins   > How would I treat? – Expert from Italy	::::	11:65 Case presentation from Italy	Yession objectives	To learn the best practices from Germany & Italy	Attend this session if you want:	Society of Invasive Cardiology	How should I west?   Interventions of the German Society of Cardiology & the Italian	ROOM 6 With the collaboration of the Working Group on Cardiovascular	11:00-12:30 🖾 Most educational cases from Germany & Italy

> Programme to be advised soon

## ...Monday 21st September, 2015

12:00-12:30 g Anatomy	12:15	11:30	LIVE demonstration	MAIN ARENA	11:30-12:30 厚	
Anatomy	London, UK	With continuous LIVE from St. Thomas' Hospital,		London, UK	11:30-12:30 匈 LIVE demonstration from St. Thomas Hospital,	

Plenary session

> Programme to be advised soon

13:00-14:40 N	15:00~14:40 찍 Evolut R: driving optimal valve delivery &
MAIN ARENA	performance in TAVI patients
Tools & Techniques	With an unrestricted educational grant from Medtronic
(INI)	Attend this session if you want:
	To show how reduced profile delivery systems allow the

show how it improves procedural safety

To highlight latest data concerning valve performance, To demonstrate the recapturable feature of Evolut R & complications

treatment of more complex patients & reduce vascular

- hemodynamics & durability
- Session objectives

13:00 13:05 13:50 14:50

- Case demonstration
   Change in practice with lowest delivery profile
   Discussion & audience interaction
- 2 Evolut R recapturability: the new standard in TAVI
- 14:05 14:15 14:26 14:30
  - Discussion & audience interaction
  - > Valve performance: design & results
- Discussion & audience interaction
  Session evaluation & key learnings

...Monday 21st September, 2015

1843 1841 1842 1844 1844	13:00-13:45 ® ROOM 2 Symposium
> Session objectives > The latest clinical evidence > The Lotus Valve: clinical cases from real world practice > The Lotus Valve: clinical cases using the next generation device & future pipeline > Discussion & audience interaction > Session evaluation & key learnings	13:00-13:45 If the Lotus valve: clinical evidence, real world soom 2 practice & future pipeline  Symposium Attend this session if you want:  > To recognise key design features & procedural aspects of the Lotus valve  > To learn how paravalvular leak can be minimised despite anatomical complexities  > To understand the current evidence & latest clinical data
13:00 13:03 19:13 13:23 13:43	13:00-13:45 E ROOM4 Symposium
> Session objectives > Perspectives from a single centre experience > 30 days transfemoral outcomes: first results from the global registry > Novel devices for transapical TAVI > Discussion & audience interaction > Session evaluation & key learnings	Tayle second and process  Rooma  ACURATE neo technologies  Symposium  Attend this session if you want:  To review ongoing Symetis & registries  To learn about the stable & predictable implantation technique of ACURATE neo TAVI System  To hear about how the easy-to-use ACURATE neo TAVI System reduces procedural risks & complications in all access

# Programme — ...Monday 21st September, 2015 13:55-14:40 Advances in TAVI & optimal


			14:28   > Session evaluation & key learnings	14:28 > Discussion & audience interaction	្សេះខេ   > Unique characteristics of the Portico valve portfolio	treatment options	1458 Portico 27 & 29mm valves: larger valve sizes expand	base	1358 > Clinical trial update: advancing the science & evidence-	13:55 Session objectives			how Portico helped in solving them	> To review & discuss a selection of complex TAVI cases &	Portico clinical programme	To present the latest data from the St. Jude Medical	the St. Jude Medical Portico valve	To learn about the latest worldwide developments with	Attend this session if you want:	Symposium With an unrestricted educational grant from St. Jude Medical	ROOM2   key learning points	13:55-14:40 同 Advances in TAVI & optimal patient outcomes:
14:38	1431	14:24		1417	14511			1455	3551		isso	10,40								Symposium	ROOM 4	13:55-14:40
14:38   > Session evaluation & key learnings	> Watchful waiting in MR	> Intervention in MR	Controversies; watchful waiting or intervention in MR	> Focus on DMR	> Focus on FMR	how far should we go	Controversies: MitraClip patient selection in FMR & DMR -	> Local anaesthesia	> General anaesthesia	Controversies: locat or general anaestitiesid for Mittactip	י שמשומיו פטן בנייאמיו	> Session Objectives		MitraClip cases	> 10 participate in discussions concerning challenging	multidisciplinary team working	> To outline best practice for patient referral, selection &	anatomy	> To learn new tips & tricks for treating complex mitral	Attend this session if you want:	With an unrestricted educational grant from Abbott Vascular	13:55-14:40 閏 MitraClip: controversies on MR treatment

## ...Monday 21st September, 2015

14:45-15:15 E	14:45-15:15  Antithrombotic treatment after TAVI  MAIN ARENA Aftend this session if you want:	7
Plenary session	<ul> <li>To learn about the current evidence for antithrombotic therapy after TAVI</li> <li>To appreciate the Issues when balancing risks of thromboembolism &amp; bleeding in the TAVI patient</li> <li>To understand more about the phenomenon of leaflet thickening &amp; motion abnormality after TAVI</li> </ul>	
	Session objectives	
(ASS)	> Time to React@PCR	
K. U. G.	>Leaflet thickening & motion abnormality after TAVI: Imaging artefact or thromboembolic precursor?	<u>1</u>
15:01	>Time to React@PCR	
10:31	> Current antithrombotic regimes & future refinements	
15/00	> Time to React@PCR	
15:12	> Key learnings & session evaluation	
14:45-15:15 岡	14:45-15:15 閟 Late-breaking trials	
ROOM 2	Session comprising selected PCR London Valves 2015 late-	

Plenary session breaking trials

> Programme to be advised soon



## Programme -

...Monday 21st September, 2015

16:10	15:05	15:55	15:45	15:40	15:35	15:30	15:25	13:15	15:05	15:00	14:55	1450	14;45		How should I treat?	ROOM 6	14:45-16:15 📮
> Session evaluation & key learnings	> Consensus	> Discussion & audience interaction	> How did   treat? – Presenter from Sweden	> How would I treat? ~ Expert from Sweden	> How would I treat? – Expert from Israel	Case presentation from Sweden	> Consensus	> Discussion & audience interaction	> How did   treat? - Presenter from Israel	> How would I treat? — Expert from Israel	> How would I treat? — Expert from Sweden	Case presentation from Israel	> Session objectives	Attend this session if you want:  To learn the best practices from Israel & Sweden	Cardiology of the Israel Heart Society & the Working Group on Interventional Cardiology of the Swedish Society of Cardiology	With the collaboration of the Working Group on Interventional	14:45-16:15 哅 Most educational cases from Israel & Sweden

15:50		15:15	LIVE demonstration	MAINARENA	15:15-16:15 ធុ	
1500   > Time to React@PCR	CK	With continuous LIVE from St. Thomas' Hospital, London,		London, UK	15:15-16:15 퇶 LIVE demonstration from St. Thomas' Hospital,	



14:45-16:15 III Interactive case corner III

Call for Session comprising selected PCR London Valves 2015 clinical case submissions

> Programme to be advised soon

## ...Monday 21st September, 2015

21'8'1 80'91		15:02	15:57	1552	1847	1542	100	3883		1527	1992		1517	15:15						Plenary session	ROOM 2	15:15-16:15
> Time to React@PCR > Key learnings & session evaluation	management	> TAVI-related endocarditis & late valve failure: incidence &	>Time to React@PCR	> Rhythm management	> Renal failure	> Bleeding	> Stroke	> Paravalvular leak	complications	> Technical & procedural refinements to reduce long-term	> Time to React@PCR	adverse outcomes & lessons for case selection	Long-term outcomes in trials & registries: predictors of	> Session objectives		> To appreciate the limitations of currently available data	outcomes	> To understand the factors which govern long-term	TAVI	To gain an understanding of the long-term outcomes after	Attend this session if you want:	15:15-16:15 圆 Long-term outcomes after TAVI
	17:24	7871		17:58	1858		1052	542		1636	1659									Plenary session	MAIN ARENA	16:30-17:30 🖾 Advanc
	! › Key lea	> Time to	experie	Percuta	) lime to	routine	> Direct r	ime to	end or	) Indirect	Session		interver	> To glim	replace	> To appr	percuta	> To hear	Attend th	replace	mitral v	Advance

17:24	17:14		17:5e	1858		16:52	542		1636	16:36		Plenary session	MAIN ARENA	16:30-17:30 👨
Yey learnings & session evaluation	>Time to React@PCR	experience & future challenges	Percutaneous mitral valve replacement: worldwide	> Time to React@PCR	routine clinical application?	> Direct mitral valve annuloplasty: how far are we from	> Time to React@PCR	end of the tunnel?	> Indirect mitral valve annuloplasty; is there a light at the	> Session objectives	Attend this session if you want:  > To hear the latest clinical data concerning direct & indirect percutaneous mitral annuloplasty > To appreciate the challenges of percutaneous mitral valve replacement & possible technical solutions > To glimpse the future of percutaneous mitral valve intervention	replacement	mitral valve: from annuloplasty to valve	Advances in percutaneous treatment of the

15:50-16:15 🛭 Learning Carillon

Programme to be advised soon

### ...Monday 21st September, 2015

16:30-17:30 岡 The tricuspid valve: how does it work, why does it Plenary session ROOM 2 go wrong & should we fix it? Attend this session if you want:

To learn more about the function & pathophysiology of the tricuspid valve

To appreciate the optimal modes of Imaging in tricuspid valve disease

To understand current surgical & future percutaneous treatment options & when they should/should not be

Session objectives

1620 > Tricuspid anatomy & pathophysiology: valve, ventricle & pulmonary circulation

16:42 > Time to React@PCR

Which Imaging modality should I use? Echocardiography, computed tomography or cardiac magnetic resonance?

16:55 17:00 Time to React@PCR

> When should we fix it (& how)? Current surgical practice

17:08 17:13 Time to React@PCR

> Is surgery the only answer? Future interventional

17:21 > Time to React@PCR possibilities

1726 > Key learnings & session evaluation

> 16:30-17:30 👨 Learning Transapical ROOMS

> Programme to be advised soon

ROOM 4 Call for submissions

16:30-17:30 阿 Abstracts Session comprising selected PCR London Valves 2015 abstract

Programme to be advised soon

16:30-17:30 👨 Learning PVL closure

Programme to be advised soon

## Programme -

## ...Monday 21st September, 2015

		:7:55   > Session evaluation & key learnings	:7:55
		> Consensus	:750
		> Discussion & audience interaction	02/71
		> How did   treat? — Presenter from France	1730
		> How would I treat? – Expert from France	17:25
		> How would I treat? – Expert from The Netherlands	17,26
		> Case presentation from France	515(1
		> Consensus	17:10
		> Discussion & audience interaction	1750
		> How did I treat? – Presenter from The Netherlands	15:50
		> How would I treat? – Expert from The Netherlands	10%5
		> How would I treat? — Expert from France	1640
> Time to React@PCR	18:35	> Case presentation from The Netherlands	.635
Urban/im Friedrichshain/DHZB Berlin, Germany		> Session objectives	1635
With continuous LIVE from Vivantes Klinikum Ar	1730		
	LIVE demonstration	יוס ובמוזו חוב הפצר לומרוורבא ווסווו וויכ ואבנו בוומיומי מיוומיזרר	
Urban/im Friedrichshain/DHZB Berlin, Ger	MAIN ARENA	To learn the best practices from The Netherlands & France	
1/:30-18:30 @ Live demonstration from vivantes Klinikur	7/:30-18:30	Attand this specion if you want:	
		the French Society of Cardiology	
Programme to be advised soon		Interventional Cardiology of the Dutch Society of Cardiology &	
		Interventional Cardiology Group of the Working Group on	
case submissions		With the collaboration of the Atheroma Coronary &	How should I treat?
Session comprising selected PCR London Valves 2015 c.	Call for	France	ROOM 6
16:30-17:30 圆 Interactive case corner IV	16:30-17:30	16:30-18:00 📮 Most educational cases from The Netherlands &	16:30-18:00

ikum Am Germany

n Am lany

anatomies	08:00-08:45 ELearning EVOLUT R  ROOM3 Attend this session if you want:  To learn about the composition of EVOLUT R  To learn how to use EVOLUT R in regular & complex	role for a hybrid approach?  **Time to React@PCR  **Binging it all together; pragmatic recommendations  **Sex	> Session objectives  (26.07) > Why do PCI? Which patient & which lesion should we treat?  95.08 > How to do PCI before & after TAVI?  95.14 > What can we learn from the surgical experience? Is there a	<ul> <li>To appreciate the potential complexities &amp; risks of undertaking PCI in the setting of severe aortic stenosis</li> <li>To refine your case selection according to the latest clinical evidence</li> </ul>	08:00-08:30 國 Coronary artery disease & TAVI  MAIN ARENA Attend this session if you want:  Plenary session To understand the impact of coronary artery disease on	Tuesday 22 <sup>nd</sup> September, 2015	Programme
08:00-09:30   call for	95:80 15:80 60:80 60:80	08:00 08:05 08:17	technicians session	08:00-09:00   ROOM 6	08:00-09:25 🖾 Abstracts  ROOM 4 Session com  Call for submissions		
08:00-09:30 国 Interactive case corner I  Session comprising selected PCR London Valves 2015 clinical case submissions	No surplined attressures a tre way to ward:     Discussion & audience interaction     Pathways for early patient discharge after TAVI     Discussion & audience interaction     Key learnings & session evaluation	> Session objectives > Choosing the right valve for the right patient > Discussion & audience interaction > Discussion & audience interaction	Attend this session if you want:  To understand the pros & cons of different valves types & their clinical indication  To discuss ways in which anaesthetic protocols can be simplified  To share strategies for earlier patient discharge after TAVI	O8:00-09:00 © TAVI in 2015; how can we streamline the patient pathway?	Abstracts Session comprising selected PCR London Valves 2015 abstract submissions		



> Programme to be advised soon

# 

		<b>12.</b>	ROOM3	08:00-08:		£	Q			Ď.	Q		S	Q							Plenary session	MAIN ARENA	180-00:80
anatomies			M3 Attend this session if you want:	08:00-08:45 国 Learning EVOLUT R		©:28   > Key learnings & session evaluation	೧೯.25 > Bringing it all together: pragmatic recommendations	ು 17 me to React@PCR	role for a hybrid approach?	ರ್ಜ14   > What can we learn from the surgical experience? Is there a	09:09   > How to do PCI before & after TAVI?	treat?	යන   > Why do PCI? Which patient & which lesion should we	の地が   > Session objectives		evidence	<ul> <li>To refine your case selection according to the latest clinical</li> </ul>	undertaking PCI in the setting of severe aortic stenosis	To appreciate the potential complexities & risks of	TAVI outcomes	sion   > To understand the impact of coronary artery disease on	NA Attend this session if you want:	08:00-08:30 🔯 Coronary artery disease & IAVI
	08:56	15:30	08:39	0834	CE.22	08:17	(6:05	08:00					session	technicians	Nurses &	ROOM 6	100:00-00:00	00.00-00.00			Call for	ROOM 4	08:00-09:25 🕸 Abstracts
	l → Key learnings & session evaluation	Discussion & audience interaction	> Pathways for early patient discharg	> Discussion & audience interaction	> Is simplified anaesthesia the way fo	Discussion & audience interaction	Choosing the right valve for the rig	> Session objectives		To share strategies for earlier patier	simplified	To discuss ways in which anaesther	their clinical indication	> To understand the pros & cons of d	Attend this session if you want:	parnway:	Vo.vo-va.vo ta that is 2015; now can we stream	TAVE is post; bourges and store	Programme to be advised soon		submissions	Session comprising selected PCR Londo	Abstracts

ROOM 4 Session com	A PROPERTY OF THE PROPERTY OF
************	> Programme to be advised soon
08:00-09:00 E	08:00-09:00 🖾 TAVI in 2015: how can we streamline the patient ROOM6   pathway?
Nurses & technicians	Attend this session if you want:  > To understand the pros & cons of different valves types &
session	their clinical indication
	To discuss ways in which anaesthetic protocols can be
	simplified
	To share strategies for earlier patient discharge after TAVI
28:00	> Session objectives
(6:05	Choosing the right valve for the right patient
08:17	> Discussion & audience interaction
36.22	Is simplified anaesthesia the way forward?
0834	› Discussion & audience interaction
9630	Pathways for early patient discharge after TAVI

	08:00-09:30
	<u> </u>
•	Ξ
•	Interactive
	case
	e e
	8
	Ξ
;	œ
;	

Call for Session comprising selected PCR London Valves 2015 clinical case submissions

Programme to be advised soon

...Tuesday 22<sup>nd</sup> September, 2015

	- Han to Breat Or O	
	Bern, Switzerland	
1023	> With continuous LIVE from Bern University Hospital,	0630
10.20	-	LIVE demonstration
10.10	Hospital, Bern, Switzerland	MAIN ARENA
8391	08:30-09:30 卿 LIVE demonstration from Bern University	08:30-09:30
9995		
	<ul> <li>Key learnings &amp; session evaluation</li> </ul>	22.
iga a	> Time to React@PCR	36160
05-40	> Bringing it all together: the key role of Imaging	80540
(Sec.)	> Time to React@PCR	Optio
9609 9730	patient with inoperable mitral calcification	
95.50	> Treatment indications & percutaneous options in the	08:55
0615	> Time to React@PCR	0550
0630	repair	
5555		, ,
0580	<ul> <li>Percutaneous possibilities following falled surgical valve</li> </ul>	1960 
20.00	> Time to React@PCR	3337
	device selection & technical tips	
	> Valve-in-valve options for failed surgical bioprostheses:	9250
	> Session objectives	08:25
	treatment selection & interventional strategy	
How should ! treat?	To understand the key role of Imaging in guiding	
ROOM 6	procedures	
09:00-10:30	To gather practical tips & tricks for valve-in-valve	
	in patients with no surgical options	
	> To learn more about percutaneous treatment possibilities	
	Attend this session if you want:	Plenary session
ROOM 3	clinical situations	RODM 2
08:45-09:30	Percutaneous valve intervention in challenging	08:25-09:25 圆

#### 阿 Learning Lotus

Attend this session if you want:

To learn about the composition of Lotus
 To learn how to use Lotus in regular & complex anatomies

剛 Most educational cases from Denmark & Turkey › How would I treat? – Expert from Turkey
› How would I treat? – Expert from Denmark Case presentation from Turkey
 How would I treat? – Expert from Denmark Association of Percutaneous Cardiovascular Interventions of the Turkish Society of Cardiology With the collaboration of the Working Group on Interventional Cardiology of the Danish Society of Cardiology & the > Session evaluation & key learnings > How would I treat? — Expert from Turkey
> How did I treat? — Presenter from Turkey To learn the best practices from Denmark & Turkey Attend this session if you want: > Discussion & audience interaction > How did I treat? – Presenter from Denmark Case presentation from Denmark Discussion & audience interaction Session objectives Consensus

PCR London Valves Preliminary programme - Valid as of 5th June, 2015

## ...Tuesday 22<sup>nd</sup> September, 2015

09:30-10:00 阿 A friend in need is a friend indeed: tips & tricks Plenary session ROOM 2 Attend this session if you want: from the experts

> To understand how to predict complications & treat them To learn practical tips to assist difficult TAVI procedures

To gain insights into options available when TAVI procedures do not go according to plan promptly

Session objectives

0636 09:30 Time to React@PCR My closest escapes

99:43 99:45 98:60 >Time to React@PCR My top 5 tips

09:50 Time to React@PCR My closest escapes

09:52 Time to React@PCR My top 5 tips

Yey learnings & session evaluation

### 09:30-10:30 阿 Learning Portico

ROOM 3

Attend this session if you want:

To learn how to use Portico in regular & complex To learn about the composition of Portico

anatomies

09:30-10:30 同 Forum

ROOM 4 Call for case submissions Session comprising selected PCR London Valves 2015 clinical

Programme to be advised soon

#### Not to miss!

Plenary session MAIN ARENA

09:35-10:30 頃 The Great Valve Debate: how do we extend lessons from TAVI experience to the mitral valve? With an unrestricted educational grant from Edwards Lifesciences

09:35-10:30 回 Interactive case corner II

<u>ଥ</u>ା Session comprising selected PCR London Valves 2015 clinical case submissions

> Programme to be advised soon

#### 10:00-10:30 晍 Registries

Plenary session | > Programme to be advised soon

8

PCR London Valves Preliminary programme - Valld as of 5th June, 2015

# Programme ....Tuesday 22<sup>nd</sup> September, 2015

			1056 1 > Key learnings & session evaluation	:057   >Time to React@PCR	10:52   > Are sequential TAVI & Mit	1050 > Time to React@PCR	TAVI is futile?	io.46   > How severe does mitral i	10:43 Time to React@PCR	better after TAVI?	toss	1936 Time to React@PCR	1931   > Mitral regurgitation: relev	1036 > Session objectives		percutaneous valve interventions	To learn more about the	improve after TAVI	> To gain insights as to wh	the setting of severe aortic stenosis	> To understand the impo	Plenary session Attend this session if you want:	MAIN ARENA   patient	11:00-11:30 哅 The impact of mitral valve disease in the TAVI
	1255	12:13	evaluation	200	> Are sequential TAVI & MitraClip procedures ever justified?	1749	1163	How severe does mitral regurgitation need to be before	11:25	1831	> How can we predict whether mitral regurgitation will get	386	> Mitral regurgitation: relevance in TAVI patient selection			rventions	To learn more about the indications for combined		To gain insights as to whether mitral regurgitation will	tic stenosis	To understand the importance of mitral valve disease in	want: Flenary session	ROOM 2	
,	Key learnings & session evaluation	3   > Time to React@PCR	intervention (& how to overcome them)	> Top 3 anatomical challenges for percutaneous mitral valve	3 > Time to React@PCR	The key role of Imaging in diagnosis & procedural planning	<del>-</del>	problems in different patients	Primary & secondary mitral valve regurgitation; different	→ Time to React@PCR	than the aortic valve	<ul> <li>Nitral valve anatomy &amp; physiology: much more complex</li> </ul>	⇒ Session objectives		possible solutions	To identify the challenges of percutaneous treatment &	treatment	assessing mitral valve pathology & planning interventional	To appreciate the value of different Imaging tools in	physiology & the pathophysiology of mitral regurgitation	To fully understand normal mitral valve anatomy &	Attend this session if you want:	interventionist needs to know	11:00-12:30 @ Mitral valve regurgitation: what the

...Tuesday 22<sup>nd</sup> September, 2015

#### 11:00-12:30 樿 Learning Direct Flow & Symetis Attend this session if you want:



To learn about the composition of Direct Flow & Symetis

To learn how to use Direct Flow & Symetis devices in regular & complex anatomies

### 

ROOM 4

submissions Session comprising selected PCR London Valves 2015 abstract

Programme to be advised soon

#### How should I treat? 11:00-12:30 및 Most educational cases from United Kingdom & ROOM 6 With the collaboration of the British Cardiovascular Intervention Society & the Working Group on Interventional Cardiology & Switzerland

Attend this session if you want: ACS of the Swiss Society of Cardiology

To learn the best practices from United Kingdom &

#### Session objectives

Case presentation from United Kingdom

11:15 How would I treat? – Expert from Switzerland

> How would I treat? – Expert from United Kingdom

> How did I treat? – Presenter from United Kingdom

Discussion & audience interaction

11:45 Consensus

Case presentation from Switzerland

> How would I treat? — Expert from United Kingdom

> How would I treat? — Expert from Switzerland

› How did I treat? – Presenter from Switzerland

Consensus Discussion & audience interaction

Session evaluation & key learnings

## 11:00-12:30 👨 Interactive case corner III

Call for Session comprising selected PCR London Valves 2015 clinical case submissions

Programme to be advised soon



PCR London Valves Preliminary programme - Valid as of 5th June, 2015

# Programme — ....Tuesday 22<sup>rd</sup> September, 2015

		> Session evaluation & key learnings	1245
		> Time to React@PCR	13:33
		> Real world results	1543
		Advanced techniques for routine challenges	13:13
		Medical	
		> The latest technological developments from Direct Flow	1203
Session evaluation & key learnings	là45	> Session objectives	1306
› Discussion & audience interaction	:3:33		
Mitralign platform for tricuspid repair	13:55	technology	
Mitralign tricuspid repair: Echo pers	13:13	> To review the latest data concerning Direct Flow Medical	
Mitral annuloplasty data review	1302	Flow valve	
> Session objectives	3051	> To analyse advanced implant techniques using the Direct	
		Medical programme	
To present the latest clinical data		> To learn about the latest innovations in the Direct Flow	
mitral & tricuspid annuloplasty		Attend this session if you want:	
To understand the Mitralign proced		With an unrestricted educational grant from Direct Flow Medical	Symposium
Attend this session if you want:		world needs	MAIN ARENA
With an unrestricted educational grant	Symposium	13:00-14:00 🕸 Innovations in valve design which address real-	13:00-14:00 四
regurgitation	ROOM 4		
13:00-13:45 圏 Percutaneous treatment of mi	13:00-13:45	│ >Time to React@PCR	12:15
	· · · · · · · · · · · · · · · · · · ·	Bern, Switzerland	
(TNT) 1 > Programme to be advised soon	(TMT)	> With continuous LIVE from Bern University Hospital,	11.00
	Tools & Techniques		LIVE demonstration
With an unrestricted educational grant	ROOM 2	Hospital, Bern, Switzerland	MAIN ARENA
13:00-14:40 📮 Tools & Techniques	13:00-14:40 ឱ	11:30-12:30 尋 LIVE demonstration from Bern University	11:30-12:30 區

Session evaluation & key learnings	1545	
› Discussion & audience interaction	:333	
Mitralign platform for tricuspid repair	12:23	
Mitralign tricuspid repair: Echo perspective	13:13	
Mitral annuloplasty data review	13:62	
> Session objectives	13:00	
To present the latest clinical data		
Attend this session if you want:  To understand the Mitralign procedure for percutaneous		
With an unrestricted educational grant from Mitralign	Symposium	
13:00-13:45 卿 Percutaneous treatment of mitral & tricuspid	13:00-13:45 @	
(TNT) 1 > Programme to be advised soon	נאה	
	Tools & Techniques	
With an unrestricted educational grant from Valtech	ROOM 2	
13:00-[4:40 @ lools & lectiniques	13:00-14:40	

# Programme —...Tuesday 22nd September, 2015

	ROOM 4 Call for	14:40-15:20	1428	14:08 14:18	13:55		13:55-14:40 © ROOM 4 Symposium
> Programme to be advised soon	year Session comprising selected PCR London Valves 2015 clinical case submissions	14:40-15:20 即 The best 3 transcatheter valve "rescues" of the	> Discussion & audience interaction	<ul><li>Case demonstration</li><li>Heart team approach to patient selection &amp; treatment</li></ul>	<ul> <li>Session objectives</li> <li>Results from 3 prospective, randomised multi-centre trials</li> </ul>	<ul> <li>To learn about the high-quality efficacy data for percutaneous annuloplasty</li> <li>To appreciate useful tips for procedural technique that make this an easy, safe &amp; accessible procedure</li> <li>To discuss the role &amp; implementation of percutaneous annuloplasty for treatment of FMR</li> </ul>	13:55-14:40 Effective, efficient, flexible mitral annuloplasty  ROOM4 for secondary mitral regurgitation  Symposium With an unrestricted educational grant from Cardiac  Dimensions  Attend this session if you want:
	1526	15:23 15:28	15:15	15:10	15:02	14:45	14:45-15:45 E MAIN ARENA Plenary session
	<ul> <li>1536 partitioning &amp; beyond)</li> <li>&gt;Time to React@PCR</li> <li>1534 Yey learnings &amp; session evaluation</li> </ul>	Time to React@PCR  Combined percutaneous strategies (CRT, valve repair, LV)	<ul> <li>Percutaneous valve repair: immediate &amp; long-term</li> </ul>	techniques >Time to React@PCR	े I ime to кеаст@РСК > The scope of surgery: repair, replacement & combined	<ul> <li>To appreciate the limitations of current treatment options</li> <li>To explore the potential of combined treatments &amp; future alternatives</li> <li>Session objectives</li> <li>Who gets it &amp; why? And who might benefit from treatment?</li> </ul>	MAIN ARENA  the «vicious circle»  Attend this session if you want:  To understand the mechanisms of secondary mitral regurgitation & the clinical problem

#### ...Tuesday 22<sup>nd</sup> September, 2015 14:45-15:30 🏻 Achieving the best outcor

	[#			ROOM3 A	14:45-15:45 岡 山	į		1522 - >-	1817 >1	15:12 >.	3537 >1	15:02   37	1457   31	HSS -	7447							 Y	Plenary session > 7	ROOM 2 At	14:45-15:30 🛱 Ac
	To least things to deproy settlessesse	To learn bow to deploy lengt/alive	To learn about key features of lenal/alve	Attend this session if you want:	14:45-15:45 曍 Learning JenaValve		> Key learnings & session evaluation	>Time to React@PCR	> Bringing it all together: a strategy for safe early discharge	> Time to React@PCR	> Pacemakers & rhythm management	> Time to React@PCR	> Post-procedural Imaging	> Time to React@PCR	> Optimal medical therapy	י שפאוטון טשומרוויפט	Specino Objectives	management & medical therapy in your IAVI patients	יט וופמו ליומכנורמו ופרטווזוופו עםמיטוט וטי ווומשייוש, יייא מיייי	practice >To bear practical recommendations for Imaging thythm	וט טופרמפט נו וב פאוסבו וכב ספטר מו ומבוול וויש במורניי שבמי	following TAVI  To discuss the exidence hase underlying current hest	To learn more about the optimal management of patients	Attend this session if you want:	14:45-15:30 🛭 Achieving the best outcomes after TAVI
16:28	1625	16:19	(19)	16:07	I-kOS	Teco	.55A	15,47	1562	1938	1 202							Plenary session	ROOM2	15:35-16:30 🛭			Callibr		
> Key learnings & session evaluation	> Case conclusion	> Heart Team discussion	> Time to React@PCR	Does the literature help?	Case presentation up to point of Heart Team discussion	> Case conclusion	> Heart Team discussion	> Time to React@rCR	Does the literature nelp:	Case presentation up to political media regular discussion	Constitution in the point of Load Team discussion	Y Consider the Constitution of the Constitutio	> 10 at the 1state of the state	To the description of the latest evidence influences strategy	valve intervention	> To learn about the issues involved in selecting cases for	concerning challenging cases	To participate in a dynamic Heart Team discussion	Attend this session if you want:	15:35-16:30		> Programme to be advised soon		Descriptions agreement to replace the series of the series	Forum Section Competition selected BCB London Values 2015 clinical

15:45-16:45 (20 LIVE demonstration from Kerckhoff Heart and MAIN ARENA Thorax Center, Bad Nauheim, Germany

LIVE demonstration

15:45 Thorax Center, Bad Nauheim, Germany

With continuous LIVE from Kerckhoff Heart and Thorax

Center, Bad Nauheim, Germany

Time to React@PCR

#### Not to miss!

16:50-17:05 @ Closing remarks

쌍

PCR London Valves Preliminary programme - Valid as of 5th June, 2015

#### 17-LUG-2015 07:43 VEN

Numero fax

070539752

Nome


UFF. FORMAZIONE

Nome/Numero 00256806592

Pag.

Ora iniz. 17-LUG-2015 07:43 VEN

Tempo trascorso: 00'26" Modalita' : STD ECM Risultati [O.K]



DIRETTORE DEL DIPARTIMENTO PATOLOGIA CARDIACA
Dott. Maurizio Porcu